The Clinical Core of the Arizona ADCC is a consortium of five recruitment sites that function as a? standardized unit under a single Clinical Core Director. The Clinical Core maintains a target of 500? participants at all stages of the aging-dementia spectrum including 200 normal controls, 100 patients with? mild cognitive impairment (MCI), and 200 with Alzheimer's disease (AD) and other forms of degenerative? dementia. Embedded within these diagnostic categories are defined Latino and Native American cohorts.? The Clinical Core capitalizes on our multi-institutional diagnostic consensus conference, centralized data? management program, and close working relationships with each of the other Cores. It is intended to? capitalize on our multi-institutional collaborative model, address the challenges associated with a multi-site? core, and optimize the utilization of Clinical Core subjects and data in support of the unusually early? detection and tracking of AD, our strengths in brain imaging, cognitive neuroscience, neurogenomics, our? studies of several putative risk factors, and our participation in several national and international? collaboration projects. All subjects undergo standardized diagnostic testing that 1) fulfills strict entrance? criteria, 2) includes demographic, historical, medical, neurological, psychiatric, neuropsychological, and? genetic measures, 3) incorporates the NACC Uniform Data Set (UDS), and 4) employs culturally sensitive? test procedures. Patients eligible for enrollment and those completing annual follow-up are discussed in a? biweekly diagnostic consensus conference. All undergo apolipoprotein E (APOE) genotyping at entry, and? an annual standardized neuropsychological battery of tests at all sites. Patient eligibility for, and participation? in ongoing research projects is tracked and reviewed on an ongoing basis. All are offered enrolled in the? Brain Donation Program for neuropathological confirmation of clinical diagnoses, though brain donation is? not required of members of culturally sensitive diversity subgroups (Latino and Native Americans). The? particular strengths of the Clinical Core include:? 1. catchment areas throughout the state of Arizona based on a novel collaborative model that includes all? major tertiary care referral centers (BNI, MCA, SHRI, VA, UA)? 2. a scientific network of established collaborative relationships between Clinical Core neurologists and? biomedical researchers at all major research institutions in Arizona (and elsewhere)? 3. a Latino outreach program (through the collaborative efforts of the EIT and Clinical Cores) with a target? enrollment of at least 100 dementia/MCI patients and controls? 4. a Native American outreach program (through the collaborative efforts of the EIT and Clinical Cores) that? encourages the participation of Native Americans in the Clinical Core.? 5. ancillary programs of longitudinally studied aging normal controls also receive the NACC UDS supported? through other funding mechanisms. These cohorts provide unique opportunities to study the transition? between cognitive normality and MCI in persons at differential risk for AD and to capitalize on our strengths? in imaging, genomics, cognitive neuroscience, and other research methods. To address the goals of the? ADCC, subjects and data from independently funded projects are now available as a resource to other? researchers, being used in other studies, and will be followed prospectively using the UDS.?

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Center Core Grants (P30)
Project #
5P30AG019610-07
Application #
7460625
Study Section
Special Emphasis Panel (ZAG1)
Project Start
Project End
Budget Start
2007-07-01
Budget End
2008-06-30
Support Year
7
Fiscal Year
2007
Total Cost
$793,017
Indirect Cost
Name
Banner Sun Health Research Institute
Department
Type
DUNS #
960181055
City
Sun City
State
AZ
Country
United States
Zip Code
85351
Gallagher, Damien; Kiss, Alex; Lanctot, Krista et al. (2018) Depression and Risk of Alzheimer Dementia: A Longitudinal Analysis to Determine Predictors of Increased Risk among Older Adults with Depression. Am J Geriatr Psychiatry 26:819-827
Ren, Yingxue; van Blitterswijk, Marka; Allen, Mariet et al. (2018) TMEM106B haplotypes have distinct gene expression patterns in aged brain. Mol Neurodegener 13:35
Haaksma, Miriam L; Calderón-Larrañaga, Amaia; Olde Rikkert, Marcel G M et al. (2018) Cognitive and functional progression in Alzheimer disease: A prediction model of latent classes. Int J Geriatr Psychiatry 33:1057-1064
Shaltouki, Atossa; Hsieh, Chung-Han; Kim, Min Joo et al. (2018) Alpha-synuclein delays mitophagy and targeting Miro rescues neuron loss in Parkinson's models. Acta Neuropathol 136:607-620
Liu, Xiaonan; Chen, Kewei; Wu, Teresa et al. (2018) Use of multimodality imaging and artificial intelligence for diagnosis and prognosis of early stages of Alzheimer's disease. Transl Res 194:56-67
Sekar, Shobana; Cuyugan, Lori; Adkins, Jonathan et al. (2018) Circular RNA expression and regulatory network prediction in posterior cingulate astrocytes in elderly subjects. BMC Genomics 19:340
Kidana, Kiwami; Tatebe, Takuya; Ito, Kaori et al. (2018) Loss of kallikrein-related peptidase 7 exacerbates amyloid pathology in Alzheimer's disease model mice. EMBO Mol Med 10:
Ortuño-Lizarán, Isabel; Beach, Thomas G; Serrano, Geidy E et al. (2018) Phosphorylated ?-synuclein in the retina is a biomarker of Parkinson's disease pathology severity. Mov Disord 33:1315-1324
Limback-Stokin, Martin M; Krell-Roesch, Janina; Roesler, Kimberly et al. (2018) Anticholinergic Medications and Cognitive Function in Late Midlife. Alzheimer Dis Assoc Disord 32:262-264
Davis, Jeremy J (2018) Performance validity in older adults: Observed versus predicted false positive rates in relation to number of tests administered. J Clin Exp Neuropsychol 40:1013-1021

Showing the most recent 10 out of 794 publications